Although most tumor mutational burden (TMB) measurements are made from genomic DNA that has been extracted from formalin-fixed paraffin embedded tissue sections, some diagnostic tests attempt to measure TMB in circulating tumor DNA (ctDNA) extracted from blood samples; an approach referred to as blood TMB (bTMB).
bTMB is an attractive biomarker since it has the potential to bypass many of the obstacles encountered with resected and hard to biopsy tumors.
This poster describes how SeraCare developed a reference material for blood tumor mutational burden measurement.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences